209 related articles for article (PubMed ID: 1801751)
1. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H
Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H
J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515
[TBL] [Abstract][Full Text] [Related]
3. Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
Schmitt M; Kanayama N; Jänicke F; Hafter R; Graeff H
Adv Exp Med Biol; 1991; 297():111-28. PubMed ID: 1837419
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
5. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
6. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H
FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Schmitt M; Jänicke F; Moniwa N; Chucholowski N; Pache L; Graeff H
Biol Chem Hoppe Seyler; 1992 Jul; 373(7):611-22. PubMed ID: 1515091
[TBL] [Abstract][Full Text] [Related]
8. Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA).
Schmitt M; Kanayama N; Henschen A; Hollrieder A; Hafter R; Gulba D; Jänicke F; Graeff H
FEBS Lett; 1989 Sep; 255(1):83-8. PubMed ID: 2529137
[TBL] [Abstract][Full Text] [Related]
9. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
10. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
Petersen LC
Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of human tumor cell pro-urokinase by granulocyte elastase.
Kanayama N; Terao T
Jpn J Cancer Res; 1990 Oct; 81(10):994-1002. PubMed ID: 2121685
[TBL] [Abstract][Full Text] [Related]
14. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
[TBL] [Abstract][Full Text] [Related]
16. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Tang L; Han X
Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
[TBL] [Abstract][Full Text] [Related]
17. Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
Kobayashi H; Ohi H; Shinohara H; Sugimura M; Fujii T; Terao T; Schmitt M; Goretzki L; Chucholowski N; Jänicke F
Br J Cancer; 1993 Mar; 67(3):537-44. PubMed ID: 8382511
[TBL] [Abstract][Full Text] [Related]
18. A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator.
Nolli ML; Corti A; Soffientini A; Cassani G
Thromb Haemost; 1986 Oct; 56(2):214-8. PubMed ID: 2433787
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
20. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
Luparello C; Del Rosso M
Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]